Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Douglas R. Adkins, David T. Mulder et al.|Clinical Cancer Research|2020Cited by 368
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancerGiacomo Oliveira, Ravindra Uppaluri, Ann Marie Egloff et al.|Science Immunology|2023Cited by 118
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and NeckGlenn J. Hanna, Robert I. Haddad, Anne O’Neill et al.|Clinical Cancer Research|2021Cited by 104
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer respondersLiye Zhou, Ravindra Uppaluri, Zexian Zeng et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 51
Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).Ravindra Uppaluri, Douglas R. Adkins, Rebecca D. Chernock et al.|Journal of Clinical Oncology|2021Cited by 40